Difference between revisions of "Procarbazine (Matulane)"

Revision as of 18:58, 30 July 2018

General information

Class/mechanism: Hydrazine derivative, alkylator; exact mechanism not understood. May inhibit transmethylation of methionine methyl groups to tRNA, interfering with protein, RNA, and DNA synthesis. May also directly damage DNA.^[1]^[2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Diseases for which it was used

Diffuse large B-cell lymphoma

Patient drug information

History of changes in FDA indication

7/22/1969: Initial FDA approval

Also known as

Code names: NCI-C01810, Ro 4-6467/1
Generic names: ibenzmethyzin hydrochloride, ibenzmethyzine hydrochloride, P-Carbazine, procarbazine hydrochloride
Brand names: Indicarb, Matulane, Natulan, Natulanar, P-Carzine

References

[insert-1] 1.0 ^1.1 Procarbazine (Matulane) package insert

[2] Procarbazine (Matulane) package insert (locally hosted backup)

[3] Procarbazine (Matulane) patient drug information (Chemocare)

[4] Procarbazine (Matulane) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 48: / Line 48: @@
 [[Category:Mantle cell lymphoma medications]]
-[[Category:Drugs FDA approved in 1969]]
+[[Category:FDA approved in 1969]]
 [[Category:WHO Essential Cancer Medicine]]